According to S&P Global Inc. 's market intelligence and MarketSmith data, Wall Street analysts believe that 11 stocks in the S & P 500 that have fallen sharply are likely to rise at least 50% in the next 12 months, including$Dish Network (DISH.US)$、$Tesla (TSLA.US)$和$Catalent (CTLT.US)$。

So far this year, the S & P 500 is down nearly 20%, fluctuating back and forth on the edge of the bear market. 25 stocks in the S & P 500 are down more than 50% so far this year, including giants such as Tesla, Inc., Meta Platforms, AMD and Netflix Inc. With the exception of the energy sector, all sectors of the S & P 500 fell from the previous year.

In this gloomy market, analysts believe that some stocks have been mistakenly killed and will rebound sharply in the next 12 months.

The communications services sector was the sector with the biggest decline as of December 29$The Communication Services Select Sector Spdr Fund (XLC.US)$It is down 37.65% this year, making it the worst performer among the 11 sectors in the S & P 500, followed by a 36% drop in consumer discretionary.

Analysts are trying to find bargains in these hard-hit sectors.

Satellite communication company$Dish Network (DISH.US)$The share price has fallen more than 56% to about $14 this year, but analysts still believe it can return to $32.44 within 12 months-roughly the same price as at the start of the year. But maybe it's just a rosy vision, with analysts predicting a 31% drop in adjusted profits in 2022 and a further 36% in 2023.

Electric vehicle manufacturer$Tesla (TSLA.US)$Shares are down 65% this year, but wall street analysts still expect Tesla to rise, forecasting a target price of $248.38 a share within 12 months. If it can be achieved, it means that there is more than 100% room for growth. Tesla, Inc. at least has fundamental growth to support his high hopes. Analysts expect the company's adjusted earnings per share to grow by 83% in 2022 and more than 33% in 2023.

Large health-care stocks have performed relatively well this year, but there are also companies that have been oversold. Drug treatment company$Catalent (CTLT.US)$It is down more than 60% this year, but analysts insist that Catalent will be worth $74.72 a share within 12 months. The company's profits are expected to fall 15 per cent in the current fiscal year, but grow by nearly 17 per cent next year.

While analysts' advice is not necessarily correct, after a bad year in the stock market, it is still interesting to see where analysts' favorite opportunities lie.